Eisai links with Selvita for novel kinase anticancers
This article was originally published in Scrip
Executive Summary
Eisai's latest move to bolster its research and pipeline in the oncology area involves a drug discovery collaboration with the Polish firm Selvita, to identify multiple new molecules against novel kinase targets.